Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 17 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-205.92 Insider Own0.49% Shs Outstand6.62M Perf Week3.71%
Market Cap6.18M Forward P/E- EPS next Y-0.67 Insider Trans0.00% Shs Float6.59M Perf Month-22.22%
Income-17.06M PEG- EPS next Q-0.58 Inst Own6.30% Short Float2.54% Perf Quarter84.82%
Sales0.00M P/S- EPS this Y98.09% Inst Trans-1.96% Short Ratio0.13 Perf Half Y-75.50%
Book/sh0.79 P/B1.18 EPS next Y66.16% ROA-264.82% Short Interest0.17M Perf Year-99.13%
Cash/sh0.74 P/C1.26 EPS next 5Y- ROE-784.63% 52W Range0.42 - 128.00 Perf YTD-85.84%
Dividend Est.- P/FCF- EPS past 5Y-28.81% ROI-372.05% 52W High-99.27% Beta0.50
Dividend TTM- Quick Ratio2.48 Sales past 5Y0.00% Gross Margin- 52W Low122.23% ATR (14)0.13
Dividend Ex-Date- Current Ratio2.48 EPS Y/Y TTM81.88% Oper. Margin0.00% RSI (14)47.47 Volatility8.12% 10.65%
Employees10 Debt/Eq0.07 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price3.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q99.76% Payout- Rel Volume0.07 Prev Close0.98
Sales Surprise- EPS Surprise7.14% Sales Q/Q- EarningsMay 13 Avg Volume1.27M Price0.93
SMA20-0.75% SMA50-16.94% SMA200-80.80% Trades Volume91,826 Change-4.76%
Jun-10-24 07:00AM
Jun-03-24 10:52AM
May-29-24 09:15AM
May-28-24 07:27AM
May-13-24 10:20AM
08:48AM Loading…
Apr-15-24 09:00AM
Apr-03-24 09:10AM
Mar-28-24 08:30AM
Mar-11-24 09:00AM
Mar-06-24 04:15PM
Feb-20-24 08:00AM
Jan-31-24 04:05PM
08:30AM Loading…
Jan-29-24 08:30AM
Jan-22-24 04:45PM
Jan-19-24 01:09PM
Jan-18-24 01:27PM
Jan-12-24 04:05PM
Jan-11-24 08:00AM
Jan-04-24 08:05AM
Dec-12-23 08:30AM
Dec-05-23 09:00AM
Dec-04-23 04:10PM
Nov-30-23 02:53PM
Nov-14-23 04:30PM
Oct-30-23 04:33PM
Oct-27-23 08:16AM
04:19PM Loading…
Oct-26-23 04:19PM
Oct-24-23 08:00AM
Oct-16-23 08:00AM
Sep-28-23 04:02PM
Sep-25-23 08:01PM
Aug-23-23 08:00AM
Aug-14-23 04:45PM
Jul-31-23 07:00AM
Jul-13-23 12:43PM
Jul-10-23 09:55AM
Jul-05-23 07:00AM
Jun-28-23 03:49PM
Jun-23-23 09:24AM
Jun-22-23 07:00AM
Jun-09-23 04:05PM
Jun-07-23 11:00AM
Jun-06-23 05:29PM
May-22-23 07:00AM
Apr-27-23 07:00AM
Apr-26-23 08:00AM
Apr-14-23 07:00AM
Apr-06-23 07:00AM
Apr-05-23 07:00AM
Apr-04-23 09:00PM
Apr-03-23 08:00AM
Mar-31-23 04:01PM
Feb-28-23 07:00AM
Feb-22-23 08:00AM
Feb-18-23 08:42AM
Feb-17-23 04:10PM
Feb-16-23 08:00AM
Feb-01-23 07:49AM
Jan-31-23 04:05PM
Dec-29-22 09:34AM
Dec-07-22 02:37PM
Dec-06-22 04:20PM
Nov-30-22 07:00AM
Nov-14-22 04:15PM
Nov-09-22 07:00AM
Nov-08-22 03:40PM
Nov-07-22 08:00AM
Oct-26-22 10:51AM
Oct-19-22 08:00AM
Oct-13-22 07:00AM
Sep-27-22 08:00AM
Sep-08-22 08:00AM
Aug-15-22 04:15PM
Aug-02-22 07:00AM
Jul-11-22 04:05PM
Jul-04-22 03:13PM
Jun-09-22 09:00AM
Jun-01-22 09:00AM
May-20-22 09:00AM
May-19-22 09:00AM
May-16-22 08:30AM
Apr-13-22 09:00AM
Apr-05-22 07:17AM
Mar-31-22 04:30PM
Mar-25-22 12:00PM
Mar-23-22 09:00AM
Feb-14-22 09:00AM
Feb-10-22 09:46AM
Jan-06-22 03:17PM
Dec-06-21 07:10PM
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dudley Robert MichaelChief Executive OfficerSep 28 '23Buy0.5198,00049,980180,262Oct 02 04:37 PM
Fitzgerald Thomas AChief Financial OfficerSep 28 '23Buy0.5149,35025,16856,318Oct 02 04:39 PM